Overview

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Pe

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
JM 3100
Plerixafor